Related references
Note: Only part of the references are listed.Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors
Steven T. Staben et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Impact of Stereospecific Intramolecular Hydrogen Bonding on Cell Permeability and Physicochemical Properties
Bjorn Over et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
PAK signalling during the development and progression of cancer
Maria Radu et al.
NATURE REVIEWS CANCER (2014)
Synthesis and structure-activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors
Yong Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas
Silvia Licciulli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase
Val S. Goodfellow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-y1)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met
Alan B. Northrup et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model
Hoi Yee Chow et al.
CANCER RESEARCH (2012)
p21-Activated kinase inhibitors: a patent review
James J. Crawford et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Protein-Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase
Richard A. Norman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors
Chuangxing Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf-MAPK Pathways
Craig W. Menges et al.
MOLECULAR CANCER RESEARCH (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
Christy C. Ong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer
Chunling Yi et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index
Alan C. Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Gini coefficient: A new way to express selectivity of kinase inhibitors against a family of kinases
Piotr P. Graczyk
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Share Paper
